Abstract
Objective
To determine amongst patients with axSpA 1) factors associated with decreased spinal mobility and 2) whether poor mobility is a predictor of response to anti‐TNFα therapy.
Methods
A prospective UK cohort study of persons meeting ASAS criteria for axial spondyloarthritis. At recruitment, clinical and patient‐reported factors independently associated with spinal mobility (measured by BASMI) were determined. Amongst those commencing anti‐TNFα therapy, factors which were independent predictors of response was determined using ASAS, quality of life and ASDAS response criteria.
Results
1,960 participants were eligible; 70% male, median age 48 years (inter‐quartile range 37,59), median BASMI score 3.6(2.2,5.3). Factors independently associated with poor spinal mobility were: poorer function; meeting x‐ray criteria for AS; longer symptom duration; higher levels of inflammation (measured by CRP); older age; male gender; not being currently employed and lower levels of education. For 51% of participants, measured BASMI was within 1 of that estimated. Poorer mobility (higher BASMI) was an independent predictor of not meeting response criteria for ASAS20 (OR per increasing score 0.80(0.66, 0.98)), ASAS40 (0.69(0.50, 0.95)), quality of life (measured by ASQoL) (β 0.64(0.26, 1.02)), but was not related to meeting ASDAS response criteria.
Conclusions
BASMI was estimated moderately well by other routinely measured factors in patients with axSpA and was an independent predictor of response to biologic therapy for some, but not all, commonly used measures. Consensus around its role in disease monitoring and clinical decisions, particularly in the likely context of face to face consultations becoming less frequent, remains to be established.
To determine amongst patients with axSpA 1) factors associated with decreased spinal mobility and 2) whether poor mobility is a predictor of response to anti‐TNFα therapy.
Methods
A prospective UK cohort study of persons meeting ASAS criteria for axial spondyloarthritis. At recruitment, clinical and patient‐reported factors independently associated with spinal mobility (measured by BASMI) were determined. Amongst those commencing anti‐TNFα therapy, factors which were independent predictors of response was determined using ASAS, quality of life and ASDAS response criteria.
Results
1,960 participants were eligible; 70% male, median age 48 years (inter‐quartile range 37,59), median BASMI score 3.6(2.2,5.3). Factors independently associated with poor spinal mobility were: poorer function; meeting x‐ray criteria for AS; longer symptom duration; higher levels of inflammation (measured by CRP); older age; male gender; not being currently employed and lower levels of education. For 51% of participants, measured BASMI was within 1 of that estimated. Poorer mobility (higher BASMI) was an independent predictor of not meeting response criteria for ASAS20 (OR per increasing score 0.80(0.66, 0.98)), ASAS40 (0.69(0.50, 0.95)), quality of life (measured by ASQoL) (β 0.64(0.26, 1.02)), but was not related to meeting ASDAS response criteria.
Conclusions
BASMI was estimated moderately well by other routinely measured factors in patients with axSpA and was an independent predictor of response to biologic therapy for some, but not all, commonly used measures. Consensus around its role in disease monitoring and clinical decisions, particularly in the likely context of face to face consultations becoming less frequent, remains to be established.
| Original language | English |
|---|---|
| Pages (from-to) | 665-674 |
| Number of pages | 10 |
| Journal | Arthritis Care & Research |
| Volume | 74 |
| Issue number | 4 |
| Early online date | 3 Nov 2020 |
| DOIs | |
| Publication status | Published - Apr 2022 |
Bibliographical note
ACKNOWLEDGMENTSWe thank the staff who contributed to running the BSRBR-AS register and we also thank the recruiting staff at the clinical centers, details of which are available at: www.abdn.ac.uk/bsrbr-as.